Cabergoline Antiprolactin Composition for Ruminant Dry Period Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Shortened dry periods in ruminants lead to metabolic diseases and reproductive disorders, and previous attempts to reduce the dry period length have resulted in increased risks of these issues and decreased milk production.
Innovation Solution
Administration of a veterinary composition containing antiprolactin compounds, such as cabergoline, as dopamine receptor agonists during the dry period to prevent and reduce deleterious effects, while maintaining milk production capacity and quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the dry period is shortened to simplify management and reduce dietary transition time, then management complexity is reduced and lactation production period is extended, but metabolic diseases and reproductive disorders increase and milk production quality deteriorates
Solution Approach 1:
The patent introduces antiprolactin compounds (dopamine receptor agonists) as intermediary substances that mediate between the shortened dry period and the ruminant's physiological needs. These compounds act as protective agents that prevent metabolic and reproductive disorders while allowing the dry period to be shortened, thus resolving the contradiction between simplified management and maintained health status
Solution Approach 2:
The patent changes the physiological parameter of prolactin levels by administering antiprolactin compounds during the shortened dry period. This parameter change allows the animal to transition more smoothly from lactation to non-lactation state, preventing metabolic disturbances while maintaining the benefits of a shorter dry period
2Productivity
If the dry period is shortened to extend lactation production period, then productivity is improved, but milk production capacity and quality are reduced
Solution Approach 1:
The patent applies preliminary action by administering antiprolactin compounds at the beginning of the shortened dry period. This preliminary intervention prepares the ruminant's physiology for the upcoming lactation resumption, ensuring that milk production capacity is maintained even though the dry period is shortened. The compound is given before the physiological stress of the shortened transition occurs
3Loss of time
If the dry period is shortened to reduce dietary transition time, then loss of time is reduced, but metabolic balance is disturbed and disease risk increases
Solution Approach 1:
The patent converts the harmful effect of the shortened dry period (metabolic imbalance) into a beneficial situation by using antiprolactin compounds to actively prevent and treat metabolic disorders. The compound transforms the potentially harmful rapid transition into a controlled physiological process, reducing disease risk while maintaining the time savings of a shorter dry period
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of antiprolactin compounds effectively reduces metabolic diseases and reproductive disorders, improves immune status and liver functions, and extends lactation production period without affecting milk production or quality.
Implementation Method 1
The antiprolactin compounds of the veterinary compositions of the present disclosure are chosen from dopamine receptor agonist compounds derived from ergot or from agonist compounds not derived from ergot derivatives
Data Source
Figure 1
Figure 2~2B
Figure 3
AI summary
The present invention relates to a veterinary anti-prolactin composition to be administered to ruminants. Said composition includes at least one anti-prolactin compound which is an agonist for dopamine receptors and which is particularly useful for preventing and/or reducing the harmful effects in ruminants linked to use for a shortened dry period. Said composition is particularly useful for preventing and/or reducing metabolic diseases and/or reproductive disorders when lactation is resumed. The use of the veterinary anti-prolactin composition according to the invention does not adversely affect the milk-producing ability and/or the milk quality of the treated ruminants.